These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 20819446)
1. Neuroprotective effect of gypenosides against oxidative injury in the substantia nigra of a mouse model of Parkinson's disease. Wang P; Niu L; Gao L; Li WX; Jia D; Wang XL; Gao GD J Int Med Res; 2010; 38(3):1084-92. PubMed ID: 20819446 [TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice. Patil SP; Jain PD; Ghumatkar PJ; Tambe R; Sathaye S Neuroscience; 2014 Sep; 277():747-54. PubMed ID: 25108167 [TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo evidences that antioxidant action contributes to the neuroprotective effects of the neuronal nitric oxide synthase and monoamine oxidase-B inhibitor, 7-nitroindazole. Thomas B; Saravanan KS; Mohanakumar KP Neurochem Int; 2008 May; 52(6):990-1001. PubMed ID: 18164516 [TBL] [Abstract][Full Text] [Related]
4. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889 [TBL] [Abstract][Full Text] [Related]
5. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress. Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333 [TBL] [Abstract][Full Text] [Related]
6. Gypenosides protects dopaminergic neurons in primary culture against MPP(+)-induced oxidative injury. Wang P; Niu L; Guo XD; Gao L; Li WX; Jia D; Wang XL; Ma LT; Gao GD Brain Res Bull; 2010 Oct; 83(5):266-71. PubMed ID: 20615455 [TBL] [Abstract][Full Text] [Related]
7. Effects of gypenosides on anxiety disorders in MPTP-lesioned mouse model of Parkinson's disease. Shin KS; Zhao TT; Choi HS; Hwang BY; Lee CK; Lee MK Brain Res; 2014 Jun; 1567():57-65. PubMed ID: 24747613 [TBL] [Abstract][Full Text] [Related]
8. 17Beta-estradiol reduces nitrotyrosine immunoreactivity and increases SOD1 and SOD2 immunoreactivity in nigral neurons in male mice following MPTP insult. Tripanichkul W; Sripanichkulchai K; Duce JA; Finkelstein DI Brain Res; 2007 Aug; 1164():24-31. PubMed ID: 17640623 [TBL] [Abstract][Full Text] [Related]
9. Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice. Zaitone SA; Hammad LN; Farag NE Pharmacol Rep; 2013; 65(5):1213-26. PubMed ID: 24399717 [TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. Zhang W; Wang T; Qin L; Gao HM; Wilson B; Ali SF; Zhang W; Hong JS; Liu B FASEB J; 2004 Mar; 18(3):589-91. PubMed ID: 14734632 [TBL] [Abstract][Full Text] [Related]
11. Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice. Sun L; Xu S; Zhou M; Wang C; Wu Y; Chan P Brain Res; 2010 Jun; 1335():74-82. PubMed ID: 20380823 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo. Guo B; Xu D; Duan H; Du J; Zhang Z; Lee SM; Wang Y Biol Pharm Bull; 2014; 37(2):274-85. PubMed ID: 24305623 [TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease. Schmidt N; Ferger B Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221 [TBL] [Abstract][Full Text] [Related]
14. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid. Karunakaran S; Diwakar L; Saeed U; Agarwal V; Ramakrishnan S; Iyengar S; Ravindranath V FASEB J; 2007 Jul; 21(9):2226-36. PubMed ID: 17369508 [TBL] [Abstract][Full Text] [Related]
15. Methylparaben protects 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells and improved behavioral impairments in mouse model of Parkinson's disease. Kopalli SR; Noh SJ; Koppula S; Suh YH Neurotoxicology; 2013 Jan; 34():25-32. PubMed ID: 23068419 [TBL] [Abstract][Full Text] [Related]
16. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Khan MM; Ahmad A; Ishrat T; Khan MB; Hoda MN; Khuwaja G; Raza SS; Khan A; Javed H; Vaibhav K; Islam F Brain Res; 2010 Apr; 1328():139-51. PubMed ID: 20167206 [TBL] [Abstract][Full Text] [Related]
17. Neuroprotective potential of ferulic acid in the rotenone model of Parkinson's disease. Ojha S; Javed H; Azimullah S; Abul Khair SB; Haque ME Drug Des Devel Ther; 2015; 9():5499-510. PubMed ID: 26504373 [TBL] [Abstract][Full Text] [Related]
18. Baicalein protects the brain against neuron impairments induced by MPTP in C57BL/6 mice. Mu X; He GR; Yuan X; Li XX; Du GH Pharmacol Biochem Behav; 2011 Apr; 98(2):286-91. PubMed ID: 21262257 [TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system. Guo Z; Xu S; Du N; Liu J; Huang Y; Han M Neurosci Lett; 2016 Mar; 616():152-9. PubMed ID: 26827716 [TBL] [Abstract][Full Text] [Related]
20. Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson's disease treated with L-DOPA. Zhao TT; Kim KS; Shin KS; Park HJ; Kim HJ; Lee KE; Lee MK BMC Complement Altern Med; 2017 Sep; 17(1):449. PubMed ID: 28877690 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]